蛋白质错误折叠和瘤微环境动态之间的交叉对话
M Sreejith1, Sonu Benny2, Vishnu V R2
1Nazerath College of Pharmacy, Pathanamthitta, Kerala, India.
Advances in protein chemistry and structural biology
|November 27, 2025
概括
蛋白质错误折叠通过改变瘤微环境 (TME) 导致癌症进展. 了解这种相互作用揭示了癌症治疗的新疗法策略.
科学领域:
- 生物化学 生物化学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 蛋白质错误折叠导致异常结构和功能受损.
- 错误折叠的蛋白质与各种疾病有关,尤其是癌症.
- 癌细胞分泌出错折叠的蛋白质,与瘤微环境 (TME) 相互作用.
研究的目的:
- 为了探索蛋白质错折的分子基础.
- 阐明错误折叠的蛋白质在调节TME中的作用.
- 研究蛋白质错折对癌症进展和治疗策略的影响.
主要方法:
- 关于蛋白质错折和癌症的文献综述.
- 分析了将错误折叠的蛋白质与TME联系在一起的分子机制.
- 检查癌症治疗和研究中的案例研究.
主要成果:
- 蛋白质错误折叠通过增强增殖,转移和化学抵抗来驱动瘤发生.
- 错误折叠的蛋白质调节TME,影响免疫反应和瘤过程.
- 针对蛋白质错折的治疗策略在癌症治疗中表现有前途.
结论:
- 蛋白质错误折叠是癌症进展和TME调节的一个关键因素.
- 针对错误折叠的蛋白质为癌症提供了新的治疗途径.
- 对蛋白质错折和TME的进一步研究对于推进癌症疗法至关重要.
相关概念视频
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Interactions Between Signaling Pathways
7.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
Microtubule Instability
6.0K
Microtubules are hollow cylindrical filaments having a diameter of approximately 25 nm and a length that varies from 200 nm to 25 μm. GTP-bound tubulin subunits form αβ-heterodimers for microtubule assembly. These core building blocks interact longitudinally, polymerizing into protofilaments. The protofilaments then interact with one another through lateral bonding forces to form stable cylindrical microtubules. These cylindrical filaments are dynamic as they undergo repeated...
6.0K
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


